Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent

被引：6
作者：
Bertrand, Valerie [1 ]
El Haite, Abdelaziz [2 ]
Carre, Delphine [3 ]
机构：
[1] CHG Jacques Monod, Paediat Unit, BP 24, F-76083 Le Havre, France
[2] CHG Jacques Monod, Pathol Lab, Le Havre, France
[3] CHG Jacques Monod, Dermatol Unit, Le Havre, France
来源：
PEDIATRIC DERMATOLOGY | 2017年 / 34卷 / 04期
关键词：
INFLAMMATORY-BOWEL-DISEASE; LESIONS;
D O I：
10.1111/pde.13138
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Ustekinumab is approved for the treatment of psoriasis in adolescents and for the treatment of moderate to severe Crohn's disease (CD) in adults, but data are lacking in pediatric CD. We report a case of severe psoriasis induced by biotherapies in an adolescent with CD that improved after switching to ustekinumab (90 mg at weeks 0, 2, and 4 and then every 8 weeks). The patient had not experienced CD relapse after 1 year of follow-up. Ustekinumab can be an alternative therapy for psoriasis induced by biotherapies when conventional treatment fails and can maintain remission of CD.
引用
收藏
页码：E214 / E215
页数：2
相关论文
共 5 条
  • [1] Andrisani G, 2013, EUR REV MED PHARMACO, V17, P2831
  • [2] Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
    Landells, Ian
    Marano, Colleen
    Hsu, Ming-Chun
    Li, Shu
    Zhu, Yaowei
    Eichenfield, Lawrence F.
    Hoeger, Peter H.
    Menter, Alan
    Paller, Amy S.
    Taieb, Alain
    Philipp, Sandra
    Szapary, Philippe
    Randazzo, Bruce
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (04) : 594 - 603
  • [3] Anti-Tumor Necrosis Factor α-Related Psoriatic Lesions in Children with Inflammatory Bowel Disease: Case Report and Systematic Literature Review
    Romiti, Ricardo
    Araujo, Karin Milleni
    Steinwurz, Flavio
    Denadai, Rafael
    [J]. PEDIATRIC DERMATOLOGY, 2016, 33 (02) : E174 - E178
  • [4] A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα: UNITI-1
    Sandborn, William
    Gasink, Christopher
    Blank, Marion
    Lang, Yinghua
    Johanns, Jewel
    Gao, Long-Long
    Sands, Bruce
    Hanauer, Stephen
    Feagan, Brian
    Targan, Stephan
    Ghosh, Subrata
    de Villiers, Wim
    Colombel, Jean-Frederic
    Lee, Scott
    Desreumaux, Pierre
    Loftus, Edward, Jr.
    Vermeire, Severine
    Rutgeerts, Paul
    [J]. INFLAMMATORY BOWEL DISEASES, 2016, 22 : S1 - S1
  • [5] Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment
    Tillack, Cornelia
    Ehmann, Laura Maximiliane
    Friedrich, Matthias
    Laubender, Ruediger P.
    Papay, Pavol
    Vogelsang, Harald
    Stallhofer, Johannes
    Beigel, Florian
    Bedynek, Andrea
    Wetzke, Martin
    Maier, Harald
    Koburger, Maria
    Wagner, Johanna
    Glas, Juergen
    Diegelmann, Julia
    Koglin, Sarah
    Dombrowski, Yvonne
    Schauber, Juergen
    Wollenberg, Andreas
    Brand, Stephan
    [J]. GUT, 2014, 63 (04) : 567 - 577
1